Innovative Immunotherapeutic Strategies: Maximizing Treatment of Head and Neck Cancer
Released On
November 3, 2022
Expires On
November 3, 2023
Media Type
Internet
Completion Time
60 minutes
Specialty
Oncology, Surgical Oncology
Topic(s)
SCCHN, Oncology
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Med Learning Group.
This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM)
This activity is supported by an educational grant from Merck & Co., Inc.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
- Nurses — 1.0 ANNC Contact Hour
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed to meet the educational needs of medical oncologists, surgical oncologists, and other healthcare professionals who manage patients with head and neck squamous cell carcinoma.
Program Overview
This educational activity will explore the appropriate place in the therapy paradigm for immunotherapy in patients with head and neck cancer, as well as managing adverse effects of immunotherapies.
Learning Objectives
- Upon completion of this activity, participants should be able to:
-
- Summarize clinical trial data on relevant biomarkers to predict response to immunotherapy in head and neck squamous cell carcinoma (SCCHN)
- Evaluate treatment guideline considerations and clinical trial data to appropriately sequence and combine therapies in the management of SCCHN
- Evaluate strategies to identify and manage immune-related adverse events associated with immune checkpoint inhibitors
Faculty
Barbara Burtness, MD
Professor of Medicine
Co-Leader, Developmental Therapeutics Program
Interim Associate Director, Diversity Equity and Inclusion
Director, Yale Head and Neck SPORE
New Haven, CT
Saral Mehra, MD, MBA, FACS
Associate Professor of Surgery (Otolaryngology)
Section Chief, Head and Neck Surgery
Director, Fellowship in Head and Neck Surgery Yale University and Smilow Cancer Hospital at YNHHS
New Haven, CT
Lynsey Teulings, APRN
Yale Cancer Center
New Haven, CT
Physician Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
Physician Credit Designation
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in this enduring activity.
CNE Accreditation Statement
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
Nursing Credit Designation
Purpose: This program would be beneficial for nurses involved in the care of patients with squamous cell head and neck carcinoma.
CNE Credits: 1.0 ANCC Contact Hour.
Disclosure Policy Statement
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Disclosures of Conflicts of Interest
- Dr. Burtness
-
- Dr. Mehra
-
- no disclosures
- Ms. Teulings
-
- no disclosures
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse PlannerThe reviewer of this activity has nothing to disclose.
Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Debra Gordon, MS, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Daniel Dasilva, Accreditation and Outcomes Coordinator, for Med Learning Group, has nothing to disclose.
Rashado Coote, Program Coordinator for Med Learning Group, has nothing to disclose.Method of Participation
There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:
You will receive your certificate as a downloadable file.
Hardware and Software Requirements
This site is best viewed with an HTML5 compatible browser, this list includes the current versions of Microsoft Internet Explorer, Mozilla Firefox, Google Chrome, and Apple's Safari. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player. Where such software is required it will be indicated.
Disclosure of Unlabeled Use
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.
Disclaimer
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: https://www.medlearninggroup.com/privacy-policy/
Americans with Disabilities Act
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
Content - Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
- Consulting: Aduro, Alligator Bioscience, Rakuten Medical, Maverick Therapeutics, Debiopharm, Celegene, CUE Biopharma, GSK, Nanobiotix and Merck & Co., Inc. Astra Zeneca, ALX Oncology, Vaccinex, Merck KgA, Merck, Roche, Exelexis, Cue BioPharma, Nektar, Kura
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Complete pre-and-post surveys and evaluation.